With the surge in innovative drug stocks, Innovent Biologics has seen a year-to-date increase of over 150%, with a market capitalization exceeding HKD 160 billion. The Hang Seng Biotechnology Index, which heavily invests in targets like Innovent Biologics and BeiGene, has risen over 80% this year, ranking among the top performers in the overall market index.

Among the ETFs tracking the Hang Seng Biotechnology Index, the Hang Seng Healthcare ETF (159892) ranks first in its category with a scale of over HKD 6 billion. Futures for this index will also be listed on the Hong Kong Exchange on November 28, providing investors with a new risk hedging tool.

From a news perspective, the Hang Seng Indexes Company recently announced its regular quarterly index adjustment results. Innovent Biologics will be included in the Hang Seng Index and the Hang Seng China Enterprises Index. All changes will take effect after the market closes on December 5 and will be implemented on December 8.

According to calculations by China International Capital Corporation (CICC), the ETF funds tracking the Hang Seng Index amount to approximately USD 29.20 billion, while the ETFs tracking the Hang Seng China Enterprises Index and the Hang Seng Tech Index have scales of about USD 7.59 billion and USD 32.61 billion, respectively. Innovent Biologics is expected to see an inflow of over USD 364 million (estimated).